Navigation Links
Trius to Present at the Stifel Nicolaus Healthcare Conference
Date:9/13/2010

SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation to investors attending the Stifel Nicolaus Healthcare Conference on Wednesday, September 15 at 8:35 a.m. ET at the Four Seasons Hotel in Boston, MA.  

A live webcast will be available through the Investor Relations page of the Trius website at http://investor.triusrx.com. A webcast replay will be available approximately two hours after the presentation and will be archived for 30 days.

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's lead product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the first such trial to be initiated under a Special Protocol Assessment (SPA). In addition to the company's torezolid phosphate clinical program, it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
2. PacificGMP Completes GMP Product Fill for Trius Therapeutics
3. Trius Doses First Patient in Antibacterial Phase 2 Trial
4. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
5. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
6. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
7. Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
8. Trius Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting
9. Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
10. Trius Therapeutics Obtains Special Protocol Assessment With FDA for Phase 3 Study of Torezolid Phosphate
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... 14, 2017  Johnson & Weaver, LLP announces that a ... Zimmer Biomet Holdings, Inc. (NYSE: ZBH )  securities ... 2016 (the "Class Period"). Zimmer Biomet provides musculoskeletal ... reconstructive products, such as knee and hip reconstructive products. ... According to ...
(Date:1/13/2017)... , January 13, 2017 ... Reagents and Equipment Market by Method (Biochemical (Calcium ... (Biomedical, Protein Production), End User - Global Forecast ... the global market from 2016 to 2021. This ... by 2021 from USD 715.4 Million in 2016, ...
(Date:1/13/2017)... The 2016 election resulted in a ... voting in favor of legalizing cannabis for recreational use, including ... the U.S. In addition, the state of Colorado ... products sales. The ArcView Group has published an updated research ... sales in the U.S. last year reached $6.7 billion, a growth ...
Breaking Medicine Technology:
(Date:1/15/2017)... ... January 15, 2017 , ... ... Outreach is a program that strives to better communities around the world by ... community. It also provides the opportunity for team members to become involved in ...
(Date:1/15/2017)... ... January 15, 2017 , ... San Francisco Magazine recently ... Area counties for 2017. Almost 1,000 nominations were submitted and a little over ... Results were announced the magazine’s January 2017 issue . , Under the ...
(Date:1/14/2017)... ... January 14, 2017 , ... Healthy living ... line of activated charcoal products. With more and more people opting to go ... according to how they cater to specific needs. , Moody Zook focused particularly ...
(Date:1/13/2017)... ... 13, 2017 , ... People with type 2 diabetes know ... easy as checking the nutrition label on foods for grams of sugar. But ... sugar-free, proteins can influence — either positively or negatively — insulin secretion and ...
(Date:1/13/2017)... ... , ... With the increasing public preference for chemical-free personal ... alternatives for customers who have grown more conscious about maintaining their health and ... charcoal products, Moody Zook Chief Executive Officer Nate Ginsburg explained their company’s decision ...
Breaking Medicine News(10 mins):